Lyell Immunopharma, Inc.·4

Feb 12, 8:46 PM ET

Hill Stephen J. 4

4 · Lyell Immunopharma, Inc. · Filed Feb 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Lyell (LYEL) COO Stephen J. Hill Sells 1,236 Shares

What Happened
Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma (LYEL), reported a sale of 1,236 shares on 2026-02-11. The weighted-average sale price was $23.39 per share, resulting in proceeds of approximately $28,910. This was a sale (S) and not a purchase—specifically, the shares were sold to satisfy tax-withholding obligations tied to the settlement of performance-based vested restricted stock units.

Key Details

  • Transaction date: 2026-02-11; Form 4 filed 2026-02-12 (appears timely).
  • Transaction type: Sale (S); 1,236 shares disposed.
  • Price: weighted average $23.39; reported range $23.3939–$24.7850 per share (issuer/SEC can request breakdown by price).
  • Proceeds: ~ $28,910.
  • Reason/footnote: F1 — shares automatically sold to cover tax withholding from settlement of performance-based vested RSUs. F2 — weighted-average price reported; range provided.
  • Shares owned after transaction: not provided in the excerpt; see the Form 4 filing for post-transaction holdings.

Context
Sales to cover tax-withholding on vested RSUs are common and reflect a routine administrative step rather than an explicit view on the company. The filing includes a price range and notes the issuer or SEC staff can request the exact breakdown of shares sold at each price.

Insider Transaction Report

Form 4
Period: 2026-02-11
Hill Stephen J.
Chief Operating Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-02-11$23.39/sh1,236$28,91017,795 total
Footnotes (2)
  • [F1]Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units.
  • [F2]The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
Signature
/s/ Mark Meltz, Attorney-in-Fact|2026-02-12

Documents

1 file
  • 4
    form4-02132026_010228.xmlPrimary